Clinical Trial

Real-World Patterns of Utilization of Lenalidomide-based Triplet Regimens in FIrst RElapsed Multiple Myeloma Patients: Evidence From Medical Record Review

Name: Real-World Patterns of Utilization of Lenalidomide-based Triplet Regimens in FIrst RElapsed Multiple Myeloma Patients: Evidence From Medical Record Review — clinical trial record (NCT07611812)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed

View on ClinicalTrials.gov →

Summary

To compare progression-free survival (PFS) in patients with first-relapse multiple myeloma treated with Rd-based "triplets" (Daratumumab + Rd (DaraRd) vs Carfilzomib + Rd (KRd) vs. Elotuzumab + Rd (EloRd) vs. Ixazomib + Rd (IxaRd))

Trial Details

NCT Number	NCT07611812
Lead Sponsor	Fondazione IRCCS Policlinico San Matteo di Pavia
Conditions	Multiple Mieloma, First Relpase, Rd-base Triplet
Enrollment	100 participants
Start Date	2021-02-04
Primary Completion	2024-12-31 (estimated)
Study Completion	2025-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-28